Business Wire

LENOVO

21.7.2021 12:35:06 CEST | Business Wire | Press release

Share
Lenovo Research Finds the 3 Steps Businesses Can Take to Innovate Beyond Boundaries

Lenovo Group (HKSE: 992) (PINK SHEETS: LNVGY) today launches Beyond Boundaries, a new report on the state of business innovation today. The study examines how businesses are innovating their way into the post-COVID future, not just to satisfy pent-up demand and unlock growth, but also to improve their social and environmental performance.

The pandemic has acted as a catalyst for innovation - while the scientific community were producing a vaccine at unheard-of speed, commerce was quicker still in largely transforming to a work-from-anywhere model.

But how do businesses not only keep these benefits of innovation, but continue to ride the wave? To find the answers to these questions, Lenovo surveyed senior decision makers in North America, Europe, the Middle East and Asia, and Asia Pacific. The result is the ‘Beyond Boundaries’ report, a deep-dive into changing attitudes to innovation, and the tensions that exist post-pandemic for businesses looking to re-build and grow.

Report highlights include the findings that:

  • Businesses recognize that diversity is directly related to successful innovation, but there is more work to do before individuals can be their authentic selves at work.
  • Disrupting a stifling, hierarchical culture – also related to effective innovation – is far from easy. The study finds some leaders are struggling to embrace a bottom-up working environment.
  • Business agility has led to improved innovation. However, there are fears that these gains will be lost as firms transition back into the office, or adopt a hybrid model that balances on-site and remote working.

Tellingly, for all the positive talk about risk-taking and innovation, many businesses remain wary of leaping into the unknown. Six out of every ten companies (59%) say senior leadership often requests that an innovation is discontinued for being too risky or experimental. This rises to 70% in North America.

And what of the much-vaunted environmental impact of innovation? It seems that the bigger the company, the more likely it is to be using innovation to improve environmental sustainability. Encouragingly, almost half (49%) of larger businesses say a key driver of innovation is to improve their overall performance in environmental sustainability.

Meanwhile 60% of larger businesses say the crisis catalyzed their efforts to use innovation to improve their social and environmental performance, compared with 54% of all those surveyed.

“Over the past year, COVID challenged everyone and changed everything – so we responded to the challenge with what we know best: innovation,” said Yuanqing Yang, Lenovo Chairman and CEO. “Now, on the threshold of the next reality, innovation remains key to unlocking our full potential. As we transform from a leading device maker to a global technology powerhouse, capable of solving the most challenging problems faced by our customers and the wider world, this commitment to innovation is more crucial than ever.

“For us, innovation is by its nature unpredictable, and is applied in unexpected places – such as revolutionizing hybrid working environments and improving environmental and corporate governance practices. But none of this happens in a vacuum, which is why we talked to business leaders around the world about what comes next – and how together, a focus on innovation can help us change the world for the better.”

Other highlights include the findings that:

  • Senior leaders say they want to step back and let innovation flourish, but the experience of junior executives suggests otherwise.
  • Innovation relies on diversity, but the ability to “fit the mold” helps if you want to challenge the status quo.
  • To unlock the next level of innovation, businesses should use technology to build on COVID-era openness and collaboration.

You can read the full report here .

About Lenovo

Lenovo (HKSE: 992) (PINK SHEETS: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye